The Asan–Samsung collaboration shows radiologists and pulmonologists jointly converting AI-quantified CT fibrosis into supplemental risk signals used alongside conventional lung-function tests. External validation supported the same one-year change threshold tied to transplant or death risk, strengthening the case for imaging biomarkers in idiopathic pulmonary fibrosis. It matters because clinical AI that changes counseling needs specialty co-ownership, not a radiology silo alone. Caveat: imaging scores remain adjuncts until guidelines, multi-center data and payers absorb them into routine practice.